LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Ascendis Pharma A-S ADR

Cerrado

SectorSanidad

203.18 -1.05

Resumen

Variación precio

24h

Actual

Mínimo

200.97

Máximo

205.63

Métricas clave

By Trading Economics

Ingresos

56M

-39M

Ventas

57M

158M

Margen de beneficios

-24.585

Empleados

1,017

EBITDA

51M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+22.03% upside

Dividendos

By Dow Jones

Próximas Ganancias

13 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

624M

12B

Apertura anterior

204.23

Cierre anterior

203.18

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

173 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2025, 23:59 UTC

Adquisiciones, fusiones, absorciones

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept 2025, 22:02 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Tron Shares Rise After New Investment From Bravemorning

8 sept 2025, 16:14 UTC

Principales Movimientos del Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept 2025, 16:13 UTC

Principales Movimientos del Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept 2025, 22:56 UTC

Charlas de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept 2025, 22:23 UTC

Charlas de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept 2025, 21:51 UTC

Charlas de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept 2025, 21:47 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 sept 2025, 21:33 UTC

Adquisiciones, fusiones, absorciones

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept 2025, 21:19 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 19:33 UTC

Charlas de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept 2025, 19:22 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept 2025, 19:02 UTC

Charlas de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept 2025, 17:29 UTC

Charlas de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept 2025, 16:59 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept 2025, 16:36 UTC

Charlas de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 16:16 UTC

Ganancias

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 sept 2025, 16:04 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR previsión

Precio Objetivo

By TipRanks

22.03% repunte

Estimación a 12 Meses

Media 250.44 USD  22.03%

Máximo 307 USD

Mínimo 203 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

16

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

173 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat